The Delaware Court of Chancery has blocked the directors of the biotechnology firm Sorrento Therapeutics Inc. from invoking business judgment protections to guard against derivative claims that they used two schemes to siphon value away from the company and into their own pockets.
Instead, Vice Chancellor Tamika Montgomery-Reeves said it was up to defendants to prove that the actions were fair to the company and its stockholders.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
